Antarctic krill source xanthine oxidase inhibitory peptide and application thereof

By using virtual screening and molecular docking technology, a highly active xanthine oxidase inhibitory peptide, WRIPSRL, was screened from Antarctic krill protein, which solved the problems of insufficient activity and low screening efficiency in existing technologies, and achieved a highly efficient and low-dose XO inhibition effect.

CN122167551APending Publication Date: 2026-06-09OCEAN UNIV OF CHINA +1
0 Cites 0 Cited by

Patent Information

Application Number
CN202610488270.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-04-14
Publication Date
2026-06-09

AI Technical Summary

Technical Problem

There is still room for improvement in the activity of XO inhibitory peptides in existing technologies. Traditional screening methods are inefficient and research on XO inhibitory peptides from Antarctic krill is insufficient, making it difficult to meet the clinical needs for high efficiency and low dosage.

Method used

Using virtual screening technology combined with molecular docking and in vitro validation, a xanthine oxidase inhibitory peptide, WRIPSRL, with the amino acid sequence Trp-Arg-Ile-Pro-Ser-Arg-Leu, was screened from Antarctic krill protein. Its high efficiency in inhibiting xanthine oxidase activity was verified through virtual enzymatic digestion, activity prediction, toxicity screening, and molecular docking.

Benefits of technology

A highly active xanthine oxidase inhibitory peptide with an IC50 value of 1.04 mM was obtained, which significantly improved the inhibitory effect and provided an efficient screening method, reducing cost and time requirements.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses an Antarctic krill source xanthine oxidase inhibitory peptide and application thereof, belongs to the technical field of biology, and particularly relates to a bioactive peptide technology. The xanthine oxidase inhibitory peptide WRIPSRL with an amino acid sequence as shown in SEQ ID NO: 1 is obtained by taking euphausia superba protein as a raw material through virtual screening, molecular docking and in-vitro activity verification technologies. According to the invention, virtual hydrolysis is carried out by using a BIOPEP-UWM platform, and candidate peptides are obtained through PeptideRanker activity prediction and ToxinPred toxicity screening; carrying out molecular docking with a xanthine oxidase crystal structure 1N5X through an Autolock Vina algorithm, and screening out a high-affinity peptide fragment; in-vitro activity determination shows that the IC50 value of the WRIPSRL peptide fragment is 1.04 mM, and the inhibition rate under the concentration of 1 mM reaches 48.68%.
Need to check novelty before this filing date? Find Prior Art